Dr Daniel Michael Strickland, MD in Lansing, NC - Medicare Obstetrics & Gynecology

Dr Daniel Michael Strickland, MD is a medicare enrolled "Obstetrics & Gynecology - Obstetrics" physician in Lansing, North Carolina. His current practice location is 415 Brenna Ln, Usps 10, Lansing, North Carolina. You can reach out to his office (for appointments etc.) via phone at (336) 384-4915.

Dr Daniel Michael Strickland is licensed to practice in North Carolina (license number 35762) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1992703607.

Contact Information

	Dr Daniel Michael Strickland, MD
	415 Brenna Ln, Usps 10, Lansing, NC 28643-9416
	(336) 384-4915
	(336) 384-4915

Physician's Profile

Full Name	Dr Daniel Michael Strickland
Gender	Male
Speciality	Obstetrics & Gynecology - Obstetrics
Location	415 Brenna Ln, Lansing, North Carolina
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1992703607
Provider Enumeration Date: 07/07/2005
Last Update Date: 09/25/2012

Medicare PECOS Information:

PECOS PAC ID: 2466497672
Enrollment ID: I20050628000072

Medical Identifiers

Medical identifiers for Dr Daniel Michael Strickland such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1992703607	NPI	-	NPPES
891098U	Medicaid	NC
1098U	Other		BCBS
81749	Other		MEDCOST

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207VE0102X	Obstetrics & Gynecology - Reproductive Endocrinology	35762 (North Carolina)	Secondary
207VG0400X	Obstetrics & Gynecology - Gynecology	35762 (North Carolina)	Secondary
207VX0000X	Obstetrics & Gynecology - Obstetrics	35762 (North Carolina)	Primary
208D00000X	General Practice	35762 (North Carolina)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Daniel Michael Strickland is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Daniel Michael Strickland, MD Po Box 10, 415 Brenna Ln, Lansing, NC 28643-0010 Ph: (336) 384-4915	Dr Daniel Michael Strickland, MD 415 Brenna Ln, Usps 10, Lansing, NC 28643-9416 Ph: (336) 384-4915

News Archive

Neurotechnology's SentiSight 3.0 SDK now available for universal object recognition

Neurotechnology, a provider of high-precision biometric and object identification technologies, today announced the availability of SentiSight 3.0, a Software Development Kit (SDK) for universal object recognition.

Research provides new insights into the origin of brown fat cells

Scientists from ETH Zurich have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

A Food and Drug Administration (FDA) panel created history by recommending a gene therapy for patients with cancer. In this therapy the patient's own genes would be modified to fight the cancer cells. The patient's cells which are thus altered to treat the cancer would thus be termed as "living drugs" as they act as soldiers to treat the cancer. These cells boost up the immune system and help the body fight the cancer.

Five-year old Pennsylvanian boy dies of H1N1 flu complications

The Department of Health today confirmed that a five-year old Adams County boy died on Oct. 31 as a result of complications from H1N1 flu. This is Pennsylvania's first pediatric death associated with H1N1.

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

IDM Pharma, Inc. ( NASDAQ:IDMI ) announced today that it received a not approvable letter from the U.S. Food and Drug Administration (FDA) after completing the review of the new drug application (NDA) for the investigational drug mifamurtide (L-MTP-PE), formerly known as Junovan, for the treatment of non-metastatic osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

Dr Daniel Michael Strickland, MD - Medicare Obstetrics & Gynecology in Lansing, NC